Abstract: The invention relates to medicine, specifically, to methods of obtaining biologically active substances with immuno-regulating properties, and can be used in medicine and veterinary science and in experimental biochemistry. The fundamental problem addressed by the invention is that of producing a noval synthetic biologically active peptide with immuno-regulating properties and of the formula: X-Glu-Trp-Y, in which X is H or Gly, Ala, Leu, Ile, Val, NVal, Pro, Tyr, Phe, Trp, D-Ala, D-Leu, D-Ile, D-Val, D-NVal, D-Pro, D-Tyr, D-Phe, D-Trp, .gamma.-aminobutyric acid, .zeta.-aminocapronic acid; Y is Gla, Ala, Leu, Ile, Val, NVal, Pro, Tyr, Phe, Trp, D-Ala, D-Leu, D-Ile, D-Val, D-NVal, D-Pro, D-Tyr, D-Phe, D-Trp, .gamma.-aminobutyric acid .zeta.-aminocapronic acid, --OH, NH.sub.2,N.sub.2 H.sub.3, mono- or di-substituted amide (C.sub.1 -C.sub.3).

Abstract: A method for reducing cancerous tumors is disclosed. The method includes administering to a mammal an effective amount of epinephrine. In another embodiment, the mammal is immediately immobilized after receiving injections of epinephrine. In a most preferred embodiment, the method also includes administering an effective amount of a cardioselective adrenergic blocking agent prior to administering of epinephrine.

Abstract: A polyclonal or monoclonal antibody recognizing specifically cortisol in a urine medium produced by immunization of animals against an immunogen compound composed of the hapten cortisol-3-carboxymethyloxime (syn isomer), coupled by its carboxyl function to a macromolecule, an immunoasay process for cortisol, particularly urinary cortisol, an assay kit and novel derivatives of coritsol.

Abstract: Process for the identification or assay of a particular polypeptide antigen X in which an immunological determination of the presence of said polypeptide antigen X is carried out in a sample, characterized in that the sample is treated in vitro using at least one chemical reagent reactingon an epsilon -NH.sub.2 function of a lysine residue oron a terminal alpha -NH.sub.2 function of a peptidein order to carry out the linking of said reagent to said polypeptide antigen X and in this way to obtain a modified polypeptide antigen X, (polypeptide antigen Xm), the immunological determination of the presence of said polypeptide antigen X in said sample is then carried out using at least one antibody produced by immunization against a polypeptide antigen Y identical to the polypeptide antigen Xm or to an antigenic fragment of this antigen Xm.

Abstract: Soluble, single chain T cell receptors, nucleic acid sequences, particularly DNA sequences, encoding the soluble, single chain T cell receptor, expression vectors containing the DNA sequences, and host cells containing the expression vectors.

Abstract: A preparation for lysing erythrocytes, characterized herein so far as the aqueous preparation with a substantially physiological ionic strength comprising a mixture:of an aliphatic aldehyde,of a polyhydric alcohol and,of a salt of a strong acid and of an alkali metal or an alkaline earth metal.

Abstract: A method for protecting leukocytes in a blood sample, comprising contacting the blood sample with a preparation comprising an aliphatic aldehyde, a salt of an alkali metal or an alkaline earth metal, and optionally an agent to adjust isotonicity and hypotonically lysing erythrocytes in the blood sample.

Abstract: A therapeutic kit which includes at least three unlinked monoclonal antibodies for neutralizing a short life IL-6 cytokine and a method for preparing said kit.

Abstract: The present invention is concerned with a whey protein composition comprising a suitable concentration of whey protein concentrate wherein the whey protein concentrate contains proteins which are present in an essentially undenatured state and wherein the biological activity of the whey protein concentrate is dependent on the overall amino acid and small peptides pattern resulting from the contribution of all its protein components and a method of producing said whey protein composition. The invention also relates to several applications of said composition.

Abstract: Process for the identification or determination of proteins by producing antibodies with the aid of peptides that are made immunogenic if necessary, and then using the resulting antibodies to determine the proteins of interest, starting with a sample that contains these and which is treated to liberate the said peptides, in which process the said peptide is so chosen that it matches a known amino acid sequence of the said protein and is used as a protein fragment that the protein can be made to release on enzymatic treatment, after which it is synthesized, the invention also relating to the applications of this process for the identification or the determination of proteins.

Abstract: Derivatives of biologically active molecules containing a primary amine group and a hydroxylated nucleus, and their addition salts with mineral or organic acids, having general formula I:R'R"N--A--B--O--CH.sub.2 --CO--NH--R (I)A=linear or branched C.sub.1 -C.sub.5 alkylene;B=C.sub.4 -C.sub.10 aromatic nucleus with optional heteroatom, or=group --B.sub.1 --X--B.sub.2 --, wherein X=O or C.sub.1 -C.sub.4 alkylene;--NH--R=amine residue or alcohol residue; andR', R"=C.sub.1 -C.sub.5 alkyl, H or hydrophobic radical, and their addition salts with mineral or organic acids, method of preparation, applications, especially to visualization, purification, the preparation of antibodies and the assay of the total hormone, and as drugs, compositions in which they are present and analytical kits.

Abstract: Derivatives comprising two hydrophilic haptens and an effector group comprising a radioactive isotope or known to be able to be labelled by a radioactive isotope or comprising an active principle or known to be able to bind an active principle, linked by a connecting bridge application to diagnosis and to therapeutics, diagnostic or therapeutic kits and immunological reagents containing them.

Abstract: Immunological reagents, consisting of a) antibody or fragment conjugates having both an anti-cell specificity and an anti-hapten specificity, and b) synthetic tracers containing at least two hapten sites and at least one site suitable to attach radioactive isotopes, paramagnetic ions, drugs or toxins, are provided. These reagents are capable of binding to target cells in a specific way, and the tracer localizes preferentially on the membrane of antigen-bearing cells, even in the presence of excess antibody conjugate (affinity enhancement). These reagents are usefully employed, either in vitro or in vivo, to detect tumors, metastases, or other tissue injuries, when the synthetic tracer carries radioactive or paramagnetic compounds, and to kill target cells when the synthetic tracer carries radioactive compounds or drugs or toxins.

Abstract: The invention relates to a product to permit separation of cells in the domain of immunopurification and consisting of a finely divided carrier of a density lower than that of the medium from which such cells must be extracted, such carrier being covered with macromolecules capable of being specifically fixed to the cells to be extracted to which a priviliged orientation was given to enable fixation of such macromolecules.

Abstract: The invention relates to a product to permit separation of cells in the domain of immunopurification and consisting of a finely divided carrier of a density lower than that of the medium from which such cells must be extracted, such carrier being covered with macromolecules capable of being specifically fixed to the cells to be extracted to which a privileged orientation was given to enable fixation of such macromolecules.

Abstract: The invention relates to a method of immunoassay for monoamines (molecules having a primary or secondary amine function) comprising chemical quantitative conversion of such amines into derivatives of higher molecular weight, which thereafter are brought into competition with radioactive analogous, or analogous carrying a tracer, for fixation to an antibody capable of recognizing all of them.

Abstract: The invention relates to a process for producing FVIII/vWF complexes for therapeutical use possessing both haemophilic A activity and Willebrand activity as well as a high degree of purity, such process substantially comprising the steps of fixing the FVIII/vWF complex in physiological conditions on a particular monoclonal antibody and releasing said complex by means of a suitable elution medium having no effct on the functions of the FVIII/vWF complex but able to dissociate the bonds linking the selected monoclonal anitbody to the FVIII/vWF complex, then collecting the latter in a highly purified form.